Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Gene Therapy (SPVN20) in Subjects With Rod-Cone Dystrophy

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
This open-label, multi-center study is to evaluate the safety, tolerability, and efficacy of escalating doses of a gene therapy called SPVN20 administered via a single intravitreal injection in participants with advanced Rod-Cone Dystrophy.
Epistemonikos ID: 1573e1cc90816cbe4fc371a961e80d53aee34495
First added on: Sep 09, 2026